Start-Up Spotlight: Elixir Works To 'Uncage' The Coronary After Intervention
The company is sponsoring INFINITY SWEDEHEART, a randomized trial of its DynamX Bioadaptor, a unique metallic coronary artery implant that adapts to vessel physiology.
You may also be interested in...
Biotronik is touting successful clinical trial results with its Orsiro sirolimus-eluting coronary stent while continuing to develop a resorbable stent.
The 2018 EuroPCR meeting in Paris featured new results from clinical trials of coronary stents from Biotronik, Amaranth, Medtronic, MicroPort, and Hexacath.
Abbott is giving up on selling its first-generation biosorbable coronary stent, which failed to match the performance of contemporary metallic drug-eluting stents in clinical trials. The company says it will continue working on the next-generation biosorbable stents and continue the ongoing trials of Absorb GT1 BVS.